Merck KGaA snags rights to 30 BMS meds; Shire taps Bacardi exec as new CFO

> Merck KGaA bought the rights to distribute 30 of Bristol-Myers Squibb's prescription drugs in Argentina, Chile and five other Latin American countries for an undisclosed price. Report

> Shire named Graham Hetherington as its new CFO and director as of July 1; Hetherington, formerly CFO of Bacardi, will replace Angus Russell, who's taking over as CEO of the U.K.-based drugmaker. Release

> Allergan has inked a deal to buy QLT's Aczone gel 5 percent product, a topical treatment for acne vulgaris, for $150 million. Report

Perrigo filed an abbreviated new drug application with the FDA to market a generic version of Medicis Pharmaceuticals' Vanos cream; Medicis already has filed suit to keep the copy off the market. Report

> When asked which company stood out at last week's ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to a survey by oncology data specialist AlphaDetail. Release

> Express Scripts is selling its infusion pharmacy business to a subsidiary of Walgreen for an undisclosed amount, the pharmacy benefit manager announced Tuesday. Report

> The RPM Report focuses on a new effort to revise and improve the way the FDA approves proposed proprietary drug names. Report

> The University of Miami medical school says that a new, 1.4 million square foot laboratory complex will help propel development of a new biotech cluster in the region. Report

> Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Report

> CytRx has inked a deal to buy Innovive Pharmaceuticals, adding its four experimental oncology therapies to its pipeline. Report

And Finally... Medical researchers are homing in on a wonder drug that may significantly reduce the risk of heart disease, cancer, diabetes and many other diseases--sunshine. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.